James Gubitosa
Cardiovascular Disease · la Follette, TNNPI 1285193201
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,339 of the $2,708 with a category attached, or 86.3%. 30 manufacturers reported payments, led by Abiomed at 24.5% of the total. Reporting peaked in 2023 at $997 and has fallen 52.0% since, to $479 in 2025.
Across 114 payments — averaging $23.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$665
- Actelion Pharmaceuticals US, Inc.$305
- Abbott$288
- Pfizer$196
- Amgen$191
- Alnylam Pharmaceuticals Inc.$125
- plus $940 from 24 others
What the payments were for
- Food & beverage$2,33986%
- Education$37014%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 15 | $665 |
| Actelion Pharmaceuticals US, Inc. | 13 | $305 |
| Abbott | 2 | $288 |
| Pfizer | 12 | $196 |
| Amgen | 9 | $191 |
| Alnylam Pharmaceuticals Inc. | 7 | $125 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $121 |
| Philips North America LLC | 7 | $102 |
| Johnson & Johnson | 6 | $80 |
| AstraZeneca | 1 | $67 |
| Shockwave Medical, Inc | 3 | $65 |
| Novartis | 4 | $60 |
| Sanofi-aventis U.S. LLC | 3 | $56 |
| Terumo Medical Corporation | 1 | $53 |
| Boehringer Ingelheim | 2 | $34 |
| Merck | 2 | $30 |
| Baxter Healthcare | 2 | $30 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $26 |
| Electromed, Inc. | 1 | $23 |
| Pharming Healthcare, Inc. | 1 | $23 |
| Mylan Specialty L.p. | 1 | $20 |
| Altathera Pharmaceuticals LLC | 1 | $19 |
| Thrombolex, Inc. | 1 | $19 |
| Livanova USA, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $18 |
| Boston Scientific | 1 | $16 |
| Chiesi USA, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Grifols USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,708 in reported general payments places this provider in the 55th percentile of 429 cardiovascular disease providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 12 | $123 |
| Atorvastatin Calcium | 18 | $99 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in la Follette
- David MetzgerKingsport$555K
- Christopher EllisNashville$527K
- Joann LindenfeldNashville$270K
- Steven GubinMemphis$248K
- Andrew ZurickNashville$231K
- Mark ZenkerNashville$225K
- Selcuk TombulChattanooga$198K
- George CrossleyNashville$197K
- Joel PharesNashville$171K
- Arvindh KanagasundramNashville$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.